Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2014

Conditions
Neurofibromatosis Type 1Plexiform NeurofibromaNeurofibromatoses
Interventions
DRUG

RAD001: Everolimus

10 mg of RAD001 will be self-administered orally once daily continuously for one year or until unacceptable toxicity or discontinuation from the study from any other reason.

Trial Locations (1)

94010

Henri Mondor Hospital, Créteil

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT01412892 - Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas | Biotech Hunter | Biotech Hunter